Karyopharm Therapeutics Inc
KPTI
Get informed when a big investor buys or sells
+ FollowMarket Cap$48.05M
Close$
$1.36
31.7% downside
Current Fair Value
31.7% downsideOvervalued by 31.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $48.05 Million |
|---|---|
| Enterprise Value | $208.95 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-17.93 |
| Beta | 0.95 |
| Outstanding Shares | 22,014,000 |
Return
| Return on Equity | 68.07% |
|---|---|
| Return on Assets | -201.89% |
| Return on Invested Capital | 219.39% |
Valuation & Multiples
| P/E Ratio | -0.14 |
|---|---|
| PEG | -0.18 |
| Price to Sales | 0.33 |
| Price to Book Ratio | -0.13 |
| Enterprise Value to Revenue | 1.43 |
| Enterprise Value to EBIT | -4.16 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.03 |
| Debt to Equity | -0.65 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-1.37
Average shareholder expectationRevenue Estimate
$32.19 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-1.13
Average shareholder expectationRevenue Estimate
$32.93 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4007▼ 62.26% |
|---|---|
| Total Calls | 4,954,810▲ 1066.94% |
| Total Puts | 1,985,400▲ 356.94% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 83.27%▼ 3.30% |
|---|---|
| Total Invested | $102.11M▲ 46.69% |
| Investors Holding | 100▲ 24.00% |
ESG Score
No data
About Karyopharm Therapeutics Inc
CEO: Michael Kauffman